background preloader 12

Facebook Twitter


Mobile QR Codes Hit The Wall Street Journal. TAG Heuer and TAPPINN have collaborated in quite possibly the most advanced QR code campaign on record.

Mobile QR Codes Hit The Wall Street Journal

I will be writing much more about the unique model that sets TAG's effort apart from other mammoth brands using QR codes in their advertising. Email Overload Fix: 3 Sentence Emails. Email is taking up too much time in our lives.

Email Overload Fix: 3 Sentence Emails

Do yourself and your recipients a favor by making your emails 3 sentences or less. Dahlias make me smile. Imaging Biomarkers. About « Dispatches from the other side of the world. Internet Statistics & Social Media Usage. 5 Staggeringly Simple Ways to Create Custom Facebook Landing Tabs. 3Q Report VC report from OnBioVC. For those of you interested in life science VCs, M&A and IPO’s, the latest OnBioVC report is now available for download here (pdf).

3Q Report VC report from OnBioVC

Inevitably, in the current economic climate, the financial trend is a downwards one, as evidenced by the findings: 3Q Report VC report from OnBioVC. Just another WordPress site. The Cancer Plus Daily. @erohealth same here. NY Chemotherapy Foundation Symposium. NY Chemotherapy Foundation Symposium. RT @ericgarland: Scott Adams' fantastic suggestion to end political parties in America.

Imagine a democratic political system in which no one is allowed to be a member of a political party.

RT @ericgarland: Scott Adams' fantastic suggestion to end political parties in America

RockMelt - Your Browser. Re-imagined. Connect for an invitation. @rvidal no worries, can wait until during week. Can drag pdfs into Zotero or Papers, do refs from there. Get this. Gingerbread Cinnamon Rolls Recipe. Hyde Park. Big Pharma settlements with the Department of Justice - let's look at the scorecard.

Prioritizing genes associated with prostate cancer development. Our approach is based on the ideas that tumorigenesis is a continuous process and that the gene-expression signature underlying the development of bone metastases starts to form in the early stages of prostate tumorigenesis and becomes well developed in the later stages.

Prioritizing genes associated with prostate cancer development

We have assumed that combining meta-analyses of different steps of prostate carcinogenesis and assigning greater weight to more-specific data might improve identification of genes associated with prostate tumorigenesis, especially those involved in the development of bone metastases; therefore, we have up-weighted the third level of meta-analysis. First level of the meta-analysis The tendency of prostate tumor to metastasize to bone is a hallmark of prostate tumorigenesis. Breast and lung cancer also often metastasize to bone, although not as frequently as prostate cancer does. Bone-metastasizing cancers may share a gene-expression signature that predisposes them to form bone metastases. How to Export Your Facebook Friends’ E-mail Addresses.

MDACC Study Summary 2008-0805. ESPN NFL I have become that Fantasy Guy. Gmail Tests Call Recording. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial : The Lancet Oncology. Introduction Imatinib (Novartis, East Hanover, NJ, USA) is the standard of care for patients with chronic myeloid leukaemia (CML), and induces durable responses and prolongs event-free survival and progression-free survival.1—3 In the International Randomised Study of Interferon versus STI571 (IRIS) protocol,4, 5 the estimated overall survival of patients who received imatinib as initial therapy was 89% at 5 years and 85% at 8 years (93% when deaths only related to CML were considered).

Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial : The Lancet Oncology

However, current practice has been for patients to continue treatment indefinitely, and the ability of imatinib to eradicate the CML clone is uncertain. Conscious of patient safety, we believe that achievement of CMR for at least 2 years is a reasonable starting point for investigations into possible discontinuation of imatinib. In a pilot study10 of patients achieving CMR who stopped imatinib, a molecular relapse of 50% (95% CI 21—79) was reported. Methods Patients Procedures Statistical analysis Results. Teva, Sandoz May Bypass New Pathway for Copying Biologic Drugs. Companies that copy biotechnology drugs, led by Teva Pharmaceutical Industries Ltd., will be able to bypass a new process set up by the U.S. health overhaul to get their products approved, regulators said.

Teva, Sandoz May Bypass New Pathway for Copying Biologic Drugs

The Food and Drug Administration will allow generic-drug makers to use either the new system, which requires them to give proprietary data to brand-name drugmakers at the point they seek approval, or an older system used to clear novel biologics, which keeps that information private, said spokeswoman Sandy Walsh. While the FDA wasn’t expected to take an immediate stand on the process, Walsh said the new law accommodates both. While the process written into the health law, signed by President Barack Obama in March, was designed to speed up approvals by potentially allowing shorter and smaller clinical trials, it may also open generic companies to expensive and time-consuming patent litigation, said Bill Marth, president of Teva’s North America unit. Close Open Source: NASA. 50 office-speak phrases you love to hate. TGIF! It's Buzzword Bingo time - who wants to play? @christianetrue. PPC Text Ad Testing for Statistical Significance.

The onco-social Daily. News: Cancer Stem Cells Can’t Stand the Heat. Sometimes zapping a tumor with ionizing radiation doesn’t work out as planned.

News: Cancer Stem Cells Can’t Stand the Heat

The tumor shrinks at first, but stem cells within the tumor survive and eventually seed the growth of new, more aggressive tumors. Now researchers have shown that this extraordinary radiation-resistance among tumor stem cells can be dramatically lowered by heating them up. The results were obtained in highly aggressive mouse and human breast cancer tumors, but the technique could possibly be used against many types of cancer. The paper is the cover story in the October 27, 2010 issue of Science Translational Medicine. We hypothesized that the heat was sensitizing tumors mainly by disrupting their stem cells’ DNA-repair capacity.

Tips for questioning costs in today’s health care system. By Joanna Fief About two years ago in the wee hours of the morning, I found myself in a local emergency room with severe stomach pain, incessant vomiting and dehydration.

Tips for questioning costs in today’s health care system

It wasn’t pretty, and I was desperate for something – anything – to ease my pain and stop my vomiting. Gratefully, within minutes of receiving an IV with medications for pain and nausea, my symptoms subsided. MannKind Accused of Data Fraud Coverup. (Updated throughout with with more information, including comments from MannKind management and new stock price.)

MannKind Accused of Data Fraud Coverup

VALENCIA, Calif. (TheStreet) -- A MannKind (MNKD_) senior manager says he uncovered potentially serious problems with clinical trials of the company's Afrezza inhaled insulin device and accuses the company of willingly keeping the information from U.S. regulators, according to a wrongful termination lawsuit filed in September. The MannKind senior manager, John Arditi, who filed the lawsuit against the company in New Jersey Superior Court, claims he was wrongfully fired by MannKind after internal audits he conducted in November 2009 uncovered "potential fraud and scientific misconduct" involving Afrezza clinical trial data, according to a copy of the lawsuit obtained by TheStreet. My Passionate Encounter in Shanghai and a Few of my Other Experiences. Where Drugs Come From: The Numbers.

We can now answer the question: "Where do new drugs come from? ". Well, we can answer it for the period from 1998 on, at any rate. A new paper in Nature Reviews Drug Discovery takes on all 252 drugs approved by the FDA from then through 2007, and traces each of them back to their origins. Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas. This morning I was delighted to see that one of my favourite medical doctors on Twitter, Dr Anas Younes from MD Anderson, has published a paper in the New England Journal of Medicine on a clinical trial of a promising new agent in development for a particular type of lymphoma. Dr Younes is very active in social media on Twitter and Facebook and has garnered quite a following of lymphoma patients interested in learning about new treatments for the disease. This also means that patients and caregivers following him are able to find out about new clinical trials as they open up.

MD Anderson Cancer Center probably has access to more clinical trials across all tumour types than any other cancer center, offering lots of options for cancer patients to receive novel therapies that may help their condition. Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas. Money for Science May Be Scarce With New Congress. Making Sure the NIH (and Innovation) Didn’t Lose in Tuesday’s Election. The election results from Tuesday are crystal clear: the “shellacking” of the Democrats means that we have at least 2 years of gridlock ahead of us and, if the Tea Party rhetoric is to be believed, at least 2 years of close attention to budgets.

How that will affect health care remains to be seen, but the effect will almost certainly be less dramatic than politicians have promised. Health care reform will be difficult to roll back, and changes in congressional oversight won’t mean sea changes at executive branch agencies such as the Food and Drug Administration. That doesn’t mean that millions won’t be spent on lobbying or that some incremental changes may happen.

But it does mean that the health PR environment we’re in isn’t likely to change dramatically.